Oculis Holding AG (OCS) Research & Development (2022 - 2026)
Quarterly Research & Development fell 9.18% to -$17.9 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$17.7 billion through Mar 2026, down 17.6% year-over-year, with the annual reading at -$71.4 million for FY2025, 20.13% down from the prior year.
Oculis Holding AG's Research & Development history spans 5 years, with the latest figure at -$17.9 million for Q1 2026.
- Research & Development came in at -$17.9 million for Q1 2026, down from -$16.6 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of -$4.8 million in Q3 2022 to a low of -$17.6 billion in Q3 2025.
- The 5-year median for Research & Development is -$12.9 million (2024), against an average of -$2.1 billion.
- Year-over-year, Research & Development crashed 149271.33% in 2024 and then grew 1.09% in 2025.
- Oculis Holding AG's Research & Development stood at -$7.2 million in 2022, then dropped by 26.58% to -$9.1 million in 2023, then tumbled by 48.35% to -$13.4 million in 2024, then decreased by 23.82% to -$16.6 million in 2025, then fell by 7.89% to -$17.9 million in 2026.
- Per Business Quant, the three most recent readings for OCS's Research & Development are -$17.9 million (Q1 2026), -$16.6 million (Q4 2025), and -$17.6 billion (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | 626,092.00 |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | 4.32 Mn |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | -101.30 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | 1.46 Mn |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | 961.60 Mn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | 1.54 Bn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | -2.30 Mn |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | 364.87 Mn |
| 10 | Oculis Holding AG | 24.51 Bn | 24.21 Bn | - | -17.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -17.94 Mn |
| Dec 31, 2025 | -16.63 Mn |
| Sep 30, 2025 | -17.65 Bn |
| Jun 30, 2025 | -18.01 Mn |
| Mar 31, 2025 | -16.43 Mn |
| Dec 31, 2024 | -13.43 Mn |
| Sep 30, 2024 | -15.00 Bn |
| Jun 30, 2024 | -18.21 Mn |
| Mar 31, 2024 | -12.44 Mn |
| Dec 31, 2023 | -9.05 Mn |
| Sep 30, 2023 | -10.04 Mn |
| Jun 30, 2023 | -6.89 Mn |
| Mar 31, 2023 | -6.65 Mn |
| Dec 31, 2022 | -7.15 Mn |
| Sep 30, 2022 | -4.75 Mn |
| Jun 30, 2022 | -6.96 Mn |